Top Medical Searches

Spain’s Almirall warns of delay in approval for psoriasis drug

(Reuters) – Spanish pharma company Almirall said on Tuesday it expects the launch of psoriasis treatment drug, Tildrakizumab, in Europe to get delayed by at least six months due to regulatory hurdles.

 Read more…

Be Sociable, Share!
November 14th, 2017 Posted in Drug
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us